C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · IEX Real-Time Price · USD
6.43
-0.11 (-1.68%)
At close: May 2, 2024, 4:00 PM
6.69
+0.26 (4.04%)
After-hours: May 2, 2024, 7:46 PM EDT
C4 Therapeutics Revenue
In the year 2023, C4 Therapeutics had annual revenue of $20.76M, a decrease of -33.25%. Revenue in the quarter ending December 31, 2023 was $3.26M with 14.26% year-over-year growth.
Revenue (ttm)
$20.76M
Revenue Growth
-33.25%
P/S Ratio
21.32
Revenue / Employee
$143,145
Employees
145
Market Cap
442.42M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20.76M | -10.34M | -33.25% |
Dec 31, 2022 | 31.10M | -14.69M | -32.08% |
Dec 31, 2021 | 45.79M | 12.59M | 37.93% |
Dec 31, 2020 | 33.20M | 11.81M | 55.25% |
Dec 31, 2019 | 21.38M | 2.02M | 10.42% |
Dec 31, 2018 | 19.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Community Health Systems | 12.52B |
Aveanna Healthcare Holdings | 1.90B |
MultiPlan | 961.52M |
CareDx | 280.32M |
Travere Therapeutics | 145.24M |
Editas Medicine | 78.12M |
Theravance Biopharma | 57.42M |
Fulcrum Therapeutics | 2.81M |
CCCC News
- 3 days ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum - GlobeNewsWire
- 24 days ago - C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire
- 2 months ago - C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins - GlobeNewsWire
- 2 months ago - C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines - GlobeNewsWire
- 4 months ago - C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals - GlobeNewsWire